Global mRNA Vaccines Market Trends and Opportunities 2023-2033: Analytics, Machine Learning and Cloud Data Warehousing

DUBLIN, Nov. 17, 2023 /PRNewswire/ -- The "mRNA Vaccines Market Report 2023-2033" report has been added to  ResearchAndMarkets.com's offering.

Overall world revenue for the mRNA Vaccines Market, in terms of value, is forecast to surpass US$11,700.0 million in 2023, with strong revenue growth forecast through to 2033. The report identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

Extensive research has been conducted on mRNA vaccines as potential cancer therapeutics for a period exceeding two decades, yielding limited success. In recent times, there has been a notable surge in research attention towards cancer vaccines. This surge has been prompted by the remarkable and enduring responses witnessed in certain malignancies through the use of immune checkpoint inhibitors, as well as advancements in technology.

The initiation of a phase 3 clinical trial for the personalised vaccine mRNA-4157 (also referred to as V940) in conjunction with pembrolizumab (commonly known as Keytruda) was announced by Moderna and Merck on 26 July 2023. This trial aims to evaluate the efficacy of the combination therapy in high-risk patients who have previously undergone surgical intervention for melanoma. The objective of the trial is to recruit a total of 1,089 patients who are at stages IIb to IV. The primary endpoint of the trial is to assess the post-surgical recurrence-free survival of these patients. The conclusive outcomes are anticipated to be available by the year 2029

Market Dynamics

Market Driving Factors

• Growing Diverse Applications of mRNA Post COVID-19 Vaccine Success
• Significant Research Funding to Boost Market Growth
• Technological Advances Driving the Market Growth
• Rising mRNA Vaccine-based Clinical Trials

Market Restraining Factors

• Scalability and Cost-Effectiveness is Still a Major Bottleneck
• Significant Storage Challenges in Low-income Countries Likely to Challenge Industry Growth

Market Opportunities

• mRNA Cancer Vaccines
• Analytics, Machine Learning and Cloud Data Warehousing

Segments Covered in the Report

Vaccine Type

• Self-amplifying mRNA-based Vaccines
• Conventional Non-amplifying mRNA-based Vaccines

Application

• Cancer
• Infectious Disease
• Autoimmune Diseases

End-users

• Hospitals and Clinics
• Research Organisations

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 22 leading national markets.

The report also includes profiles and for some of the leading companies in the mRNA Vaccines Market, 2023 to 2033, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth

• Pfizer Inc.
• Moderna, Inc.
• BioNTech SE
• AstraZeneca
• Sanofi
• GSK plc
• Daiichi Sankyo
• Ethris GmbH
• AIM Vaccine
• Arcturus Therapeutics Inc.
• CureVac
• Sino Biopharmaceutical Co., Ltd.

Key Questions Answered in the Report:

• How is the mRNA vaccines market evolving?
• What is driving and restraining the mRNA vaccines market?
• How will each mRNA vaccines submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each mRNA vaccines submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading mRNA vaccines markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the mRNA vaccines projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of mRNA vaccines projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the mRNA vaccines market?
• Where is the mRNA vaccines market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

Forecasts to 2033 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2033, this new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

For more information about this report visit https://www.researchandmarkets.com/r/5kz1n8

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com 
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets